Cabaletta Bio Inc (CABA) Stock Price, Quote & News

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States

Achandler787 Mar. 15 at 3:31 PM

$CABA that’s great info! Def our CABA in my opinion. Earnings in March likely to have big updates - I see $6

0 · Reply

MiroslavBroz Mar. 15 at 9:10 AM

$CABA

2 · Reply

KNCourt24 Mar. 14 at 12:46 PM

$CABA Hopefully it stays above $3 before next leg up but don’t be surprised if it dips around 2.6-2.8 either way gives us time and a gift to load up way more before June💰

1 · Reply

texmade2 Mar. 13 at 10:23 PM

$CABA wow a chance to buy up more cheap ones before the run up for earnings

0 · Reply

Achandler787 Mar. 13 at 6:30 PM

$CABA we due a closing rally

0 · Reply

Madmortigan Mar. 13 at 5:21 PM

$CABA

0 · Reply

CRKissel Mar. 13 at 5:04 PM

$CABA Added

0 · Reply

Moonman321 Mar. 13 at 4:42 PM

$CABA look even the losers get a second chance Let’s see if they take advantage of it retail dummies

0 · Reply

Chrisf720 Mar. 13 at 3:58 PM

$CABA Know what you own 🥱

0 · Reply

Blaze321 Mar. 13 at 3:54 PM

$ISPC I am sorry for all the posts today but it really sucks losing ALOT of money. Thankfully I researched this company and got rid of it quickly. Hopefully you kill them on the next one. $GRCE and $CABA are on my radar. I encourage you to do some research. Good Luck All!!!

1 · Reply

Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 5, 2026, 8:00 AM EST - 5 weeks ago

Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 27, 2026, 11:01 AM EST - 6 weeks ago

Cabaletta Bio: Do You Buy With The Insiders?

Jan 12, 2026, 8:00 AM EST - 2 months ago

Cabaletta Bio Announces 2026 Strategic Priorities

Jan 12, 2026, 7:30 AM EST - 2 months ago

IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms

Dec 3, 2025, 5:23 PM EST - 3 months ago

Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 7:30 AM EST - 4 months ago

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 8:00 AM EST - 4 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

Oct 27, 2025, 7:00 AM EDT - 4 months ago

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Oct 14, 2025, 8:00 AM EDT - 5 months ago

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

Oct 9, 2025, 12:00 PM EDT - 5 months ago

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Oct 7, 2025, 6:20 AM EDT - 5 months ago

Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 7, 2025, 7:30 AM EDT - 7 months ago

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 30, 2025, 11:07 AM EDT - 8 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT NGNE NTLA QURE RCKT

Jun 11, 2025, 9:54 AM EDT - 9 months ago

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 9:49 AM EDT - 9 months ago

Cabaletta Bio: Sector Headwinds And Funding Issues

Jun 11, 2025, 6:15 AM EDT - 9 months ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:00 AM EDT - 9 months ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

May 29, 2025, 8:00 AM EDT - 10 months ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 10 months ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Feb 26, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 10:21 AM EST - 1 year ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 1 year ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 11, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Jan 29, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Jan 6, 2025, 2:28 PM EST - 1 year ago

Cabaletta Bio: Finding Optimism In Dire Straits

Oct 22, 2024, 11:41 AM EDT - 1 year ago

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 28, 2024, 1:42 PM EDT - 1 year ago

Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Jun 14, 2024, 2:00 AM EDT - 1 year ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 2 years ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 2:53 AM EST - 2 years ago

Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward

Jan 2, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 11, 2023, 5:58 AM EST - 2 years ago

Cabaletta Bio: Expanding The Success Of CAR-T Beyond Oncology

Dec 10, 2023, 2:44 AM EST - 2 years ago

Buy Cabaletta Bio's Promising SLE Treatment

Nov 28, 2023, 4:30 PM EST - 2 years ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 2 years ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 8:15 AM EST - 2 years ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Achandler787 Mar. 15 at 3:31 PM

$CABA that’s great info! Def our CABA in my opinion. Earnings in March likely to have big updates - I see $6

0 · Reply

MiroslavBroz Mar. 15 at 9:10 AM

$CABA

2 · Reply

KNCourt24 Mar. 14 at 12:46 PM

$CABA Hopefully it stays above $3 before next leg up but don’t be surprised if it dips around 2.6-2.8 either way gives us time and a gift to load up way more before June💰

1 · Reply

texmade2 Mar. 13 at 10:23 PM

$CABA wow a chance to buy up more cheap ones before the run up for earnings

0 · Reply

Achandler787 Mar. 13 at 6:30 PM

$CABA we due a closing rally

0 · Reply

Madmortigan Mar. 13 at 5:21 PM

$CABA

0 · Reply

CRKissel Mar. 13 at 5:04 PM

$CABA Added

0 · Reply

Moonman321 Mar. 13 at 4:42 PM

$CABA look even the losers get a second chance Let’s see if they take advantage of it retail dummies

0 · Reply

Chrisf720 Mar. 13 at 3:58 PM

$CABA Know what you own 🥱

0 · Reply

Blaze321 Mar. 13 at 3:54 PM

1 · Reply

Bronco6970 Mar. 13 at 3:52 PM

$CABA buy now! As soon as oil spikes more, Taco Trump will declare victory or some stupid narrative, and pull out of Iran. Market will explode. We’ve seen this playbook before. 🚀

0 · Reply

erd3312 Mar. 13 at 3:40 PM

$CABA trash stock. trash company. short short short

0 · Reply

texmade2 Mar. 13 at 2:57 PM

$CABA WELL NO WANDER

0 · Reply

Madmortigan Mar. 13 at 1:56 PM

$CABA we stuck today?

1 · Reply

Moonman321 Mar. 13 at 1:47 PM

$SKIN $CABA $NVDA

0 · Reply

robbied61 Mar. 13 at 1:18 PM

$CABA does anyone have a guess when is data coming

1 · Reply

Moonman321 Mar. 13 at 1:05 PM

$CABA $PLUG $SKIN PCE just came in 2.8% — BELOW expectations. Inflation cooling while GDP gets revised down to 0.7%. That’s the exact setup for rate cuts ahead. Lower inflation + slowing growth = Fed pressure building to ease. Watch small caps and beaten-down growth names — they move first when the market sniffs out easier money. Rotation is coming. 📈

0 · Reply

texmade2 Mar. 13 at 12:56 PM

$CABA I will get up You keep knockin’ me down, down to the floor, Think I won’t stand up anymore. But sooner or later I get back on my feet, Fire in my blood, thunder in my beat. You keep knockin’ me down, tryin’ to break my class, But sooner or later I get up… and kick your ass.

0 · Reply

MichToss99 Mar. 13 at 11:06 AM

$SLS $IBRX $AKBA $CABA $OCGN I loaded yesterday thanks Jack!

1 · Reply

am5198 Mar. 13 at 10:34 AM

$CABA let's put in a nice solid green candle today. Ill settle for 5%...😅 keep climbing, CABA.

0 · Reply

texmade2 Mar. 13 at 10:06 AM

$CABA I may have got the earnings date wrong, BUT I picked the right stock to hold.

0 · Reply

DragonAlgo Mar. 13 at 8:30 AM

🐉 $CABA CALL — DragonAlgo® Signal Contract: CABA CALL Expiry: 2026-04-17 | Strike: $5.00 | Type: CALL Option Plan (premium): Entry: $0.05 Stop: $0.04 TP1: $0.07 TP2: $0.09 TP3: $0.12 Active momentum environment. 🔗 https://dragonalgo.com

0 · Reply

Market Cap	294.57M
Revenue (ttm)	0.00
Net Income (ttm)	-115.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,476,600
Avg Vol	3,249,830
Day's Range	N/A - N/A
Shares Out	96.27M
Stochastic %K	9%
Beta	3.25
Analysts	Strong Sell
Price Target	$13.12